IRIDEX Corporation logo

IRIDEX Corporation(IRIX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.69
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for IRIX

11/13/2026: IRIX (1-star) is currently NOT-A-BUY. Pass it for now.

IRIDEX Corporation is a micro-cap medical technology company specializing in laser systems and consumable probes for ophthalmology. The company's main operational strength lies in its proprietary MicroPulse tissue-sparing technology, which supports a stable, recurring revenue stream from single-use probes. Its primary growth opportunity centers on expanding adoption of the Cyclo G6 platform and driving operational cost efficiencies. However, the company faces intense competition from large medtech conglomerates, historical net losses, and international market headwinds. IRIDEX suits speculative or growth-oriented investors willing to tolerate high volatility, while key developments to monitor include gross margin expansion, recurring probe growth, and cash flow sustainability.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitModest projected top-line growth is offset by small scale and historical unprofitability.
Momentum investorStrong fit while signal remains positiveLow stock price and small market capitalization can spark sharp short-term momentum moves on positive clinical or earnings news.
Value investorMixed fitWhile trading at a low absolute share price, the lack of consistent net earnings introduces fundamental value verification risks.
Dividend investorWeak fitIRIDEX does not pay dividends, focusing entirely on capital preservation and operational turnaround.
Low-risk investorWeak fitMicro-cap stock volatility and historical bottom-line losses present substantial equity risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighLow liquidity and small market capitalization frequently result in outsized daily price swings.
Valuation riskMedium / highValuation relies heavily on turnaround execution and future margin expansion rather than steady current earnings.
Competition risk (large medtech conglomerates)HighWell-capitalized rivals can outspend IRIDEX in marketing, research, and hospital contract bundling.
Business qualityMediumProprietary MicroPulse technology provides a defensible niche, but historical net losses weigh on overall financial quality.
Dividend incomeLow / noneNo dividend is paid, making the stock unsuitable for income-focused strategies.
Execution riskMedium / highSuccess depends heavily on successfully implementing cost-reduction efforts, facility transitions, and driving international adoption.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 12.12M USD
Price to earnings Ratio -
1Y Target Price 2.75
Price to earnings Ratio -
1Y Target Price 2.75
Volume (30-day avg) 736.0K shares
Beta 0.63
52 Weeks Range 0.61 - 1.65
Updated Date 11/15/2026
52 Weeks Range 0.61 - 1.65
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.2

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit -48.54%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
IRIX receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
IRIX has moderate overall fundamentals (3 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+50.2%) is partially offset by weak cash generation (FCF margin -4.3%), moderate revenue growth (+8.2%), weak profitability (net margin -8.4%).

Financial Health Rating

★★★★★
IRIX's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 41.3%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is IRIX's strongest growth driver at +69.1% FY2025 versus FY2024 (strong, 5 stars). By comparison, earnings growth (+50.2%, strong) is also strong, while revenue growth (+8.2%, moderate) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 18.1% and approximately 57.0% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 37.52% supports management-shareholder alignment.

Top 5 Institutional Investors

Vanguard Capital Management, LLC 2.93%
Renaissance Technologies Corp 1.90%
Morgan Stanley - Brokerage Accounts 1.74%
Weber Capital Management LLC 0.84%
Geode Capital Management, LLC 0.79%

Unit Economics (Per $1K Revenue)

★★★★★
IRIX generates approximately $367 of gross profit, $-49 of operating income, and $-43 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -1.30% (Tax Credit)

Quantitative Style Profile

★★★★★
IRIX has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Capital Equipment (Lasers)Sales of specialized laser consoles like Cyclo G6 and IQ 532/577 to clinics and hospitals.Provides initial system placements but can experience lumpy purchasing patterns.
Consumables and AccessoriesSingle-use treatment probes, EndoProbe handpieces, and delivery devices.Drives a recurring, high-margin revenue stream as installed laser consoles are actively used.
Geographic OperationsDirect and distributor-led sales spanning North America, international markets, and emerging regions.Exposes the business to varying macroeconomic and regional trade conditions.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE 769.23
Enterprise Value 17.45M
Price to Sales(TTM) 0.23
Enterprise Value 17.45M
Price to Sales(TTM) 0.23
Enterprise Value to Revenue 0.34
Enterprise Value to EBITDA -3.61
Shares Outstanding 17.56M
Shares Floating 10.02M
Shares Outstanding 17.56M
Shares Floating 10.02M
Percent Insiders 37.52
Percent Institutions 18.05

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.